Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / Wolverine blend

Wolverine blend: BPC-157 and TB-500

"Wolverine" is a seller's nickname for one vial that holds two compounds: BPC-157 and TB-500. Here is what each one is, where each stands with FDA, and what is known about the risks.

2 compounds · Not FDA-approved · Evidence grade D · Reviewed

Not approved by the FDA for human use. Not for human consumption. This page describes the blend only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer

What is in the vial

The blend, also called the Wolverine stack or Wolverine pack, combines BPC-157, a lab-made fragment of a stomach protein, with TB-500, a lab-made fragment of thymosin beta-4. It is sold online as a "research use only" powder vial. There is no approved product containing either compound, alone or together.

FDA status

BPC-157: Not approved for any use. FDA flagged it for safety concerns in 2023. In July 2026 an FDA advisory committee narrowly recommended adding it to the list of substances pharmacies may compound. The vote is advisory. It is not FDA approval, and nothing changes legally until FDA finishes rulemaking. The use the committee considered was ulcerative colitis. FDA staff had advised that it did not meet the standard for listing. In October 2026 HHS published a draft policy saying it does not intend to take action against pharmacies and physicians that compound it under set conditions while FDA decides through rulemaking. That is a decision not to enforce, not approval, and it can be withdrawn.

TB-500: Not approved for any use. In July 2026 an FDA advisory committee narrowly recommended adding it to the list of substances pharmacies may compound. The vote is advisory. It is not FDA approval, and nothing changes legally until FDA finishes rulemaking. The use the committee considered was wound healing. In October 2026 HHS published a draft policy saying it does not intend to take action against pharmacies and physicians that compound it under set conditions while FDA decides through rulemaking. That is a decision not to enforce, not approval, and it can be withdrawn.

Evidence

BPC-157: Almost entirely animal and laboratory studies. Published human data cover only a few dozen people.

TB-500: No published human trials of TB-500 itself. FDA has pointed out that human studies of thymosin beta-4 are not evidence for TB-500.

No study has tested the two together in people.

Risks

BPC-157: Long-term safety in people is unknown. It is banned in sport at all times under the World Anti-Doping Code.

TB-500: Safety in people is unknown. It is banned in sport at all times under the World Anti-Doping Code.

Products sold for "research use only" carry no assurance of identity, strength or sterility. In a blend you cannot set the two amounts separately: every draw carries both in the ratio mixed into the vial.

Related

Each compound has its own profile: BPC-157 and TB-500. Compare them side by side in BPC-157 vs TB-500, see the 2026 regulatory tracker, or work out syringe units for a two-compound vial with the blend calculator (arithmetic only).

Questions

What is the Wolverine blend?

A seller's nickname for one vial holding two compounds, BPC-157 and TB-500. Neither is approved by FDA for human use.

Is the Wolverine blend FDA-approved?

No. Neither BPC-157 nor TB-500 is approved for any use, and there is no approved product combining them. A July 2026 advisory vote and an October 2026 HHS draft policy concern pharmacy compounding of each compound, not approval.

Is it banned in sport?

Yes. Both BPC-157 and TB-500 are banned at all times under the World Anti-Doping Code.

Sources: FDA: bulk drug substances that may present significant safety risks; AJMC: FDA panel backs 6 peptides for compounding; Pharmacy Times: what the peptide vote changes; Black Health: what the FDA peptide vote changed; HHS: enforcement discretion policy for compounding certain peptides (draft); Federal Register: HHS draft peptide compounding policy, October 30, 2026; Worst Pills, Best Pills: unapproved peptides.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.